RxDoctor Payments Data

Said Issa, MD

Ophthalmology · Ann Arbor, MINPI 1003840844

Payments from drug & device makers

$706in general payments, 2019–2025

Across 20 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$125
  • Bausch & Lomb Americas Inc.$114
  • Alcon$104
  • Amgen$90
  • Glaukos Corporation$80
  • Biotissue Holdings Inc.$53
  • plus $141 from 3 others

What the payments were for

  • Food & beverage$706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$706 in reported general payments places this provider in the 40th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$103,850
Medicare patients
285
Services billed
1,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Alphagan PBrimonidine Tartrate49$13,884
Prednisolone Acetate234$9,951
Timolol Maleate188$8,004
Brimonidine Tartrate86$7,683
Latanoprost497$4,256
Ketorolac Tromethamine222$4,117
Brinzolamide20$3,309
CombiganBrimonidine Tartrate/Timolol11$2,114
MoxifloxacinMoxifloxacin Hcl90$2,039
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat39$819
Travoprost12$761
Acetazolamide ErAcetazolamide15$580
Dorzolamide Hcl21$372
Azelastine Hcl18$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Combigan$48$15,99860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →